GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with ...

Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...

It looks like SoftBank's Vision Fund 2 is coming back strong. In the last nearly two quarters, the fund has participated in ...

SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ -- IASO Biotherapeutics ('IASO Bio'), a biopharmaceutical company focused on the discovery, development, manufacturing, and ...

Leaders from BioMed Realty, Fitzsimons Innovation Community, J.P. Morgan, and Umoja Biopharma Join CBSA Board Colorado BioScience Association (CBSA), which creates co-opportunity for Colorado’s ...

IASO Bio has established multiple global collaborations and licensing agreements with leading cell therapy companies, such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, underscoring ...

Seattle, Washington-based immunotherapy start-up Umoja Biopharma closed an oversubscribed $100 million third round that will be deployed as it advances a series of preclinical-stage CAR-T ...

Leaders of three of these companies – Philadelphia’s Interius BioTherapeutics, Seattle’s Umoja BioPharma, and Boston’s Kelonia Therapeutics – spoke with pharmaphorum offering a peek into ...